by Luke Pettit | Jul 30, 2026 | US & International
As a reminder, this case addresses how the Hatch-Waxman act “carve-out” provisions (which has led to the emergence of “skinny labels”) interacts with US law on induced patent infringement. This case is the first time the US Supreme Court has had the opportunity to...
by Alyson Lam | Jul 28, 2026 | US & International
On 16–17 June 2026, the Court heard Otsuka’s appeal in Otsuka Pharmaceutical Co Ltd v Sun Pharma ANZ Pty Ltd. The appeal challenges the Full Federal Court’s finding that formulation patents are not eligible for patent term extensions (PTEs). The decision, expected in...
by Alyson Lam | Jul 14, 2026 | US & International
Overview Broad antibody claims have faced a difficult path in the US since Amgen v Sanofi, particularly where the claim covers a large functional genus. The Federal Circuit’s decision in Teva v Eli Lilly is therefore interesting because the court drew an important...
by Sean Hughes | May 11, 2026 | EPO
Sequence Identity Claims After T 0137/24 The recent Board of Appeal decision in T 0137/24 provides useful guidance on how sequence identity claims are assessed under the EPC, particularly in relation to added matter and sufficiency. Biotech sequence-related claims are...
by David Eyre | Mar 4, 2026 | US & International
Background REGENXBIO and the Trustees of the University of Pennsylvania sued Sarepta for infringing multiple claims of U.S. Patent No. 10,526,617, which is directed to cultured host cells containing a recombinant nucleic acid molecule encoding an AAV capsid sequence...
Recent Comments